Delic Corp Inc. DELCF Archives - Page 4 of 11

MondayApr 25, 2022 9:30 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Continues Investor Outreach as Psychedelic Wellness Drug Development Advances

Delic Holdings Corp operates in North America to advance the use of psychedelics in treating difficult conditions related to major depression, PTSD and anxiety The company has a three-pronged approach to promoting access and affordability for treatment drugs: conducting research in its lab facility, advancing treatment through its clinical network, and educating the public through conferences and Web-based media The use of psychedelic drugs to treat these mental health concerns is gaining credibility some 50 years after hallucinogenic drugs reached their peak use and were generally declared illegal Delic recently received Health Canada authorization to obtain 60 grams of psilocybin…

WednesdayApr 20, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Achieves Key Milestone in the Advancement of Its Research Efforts

Delic Labs just received its Health Canada 56 Research Exemption, enabling it to develop innovative analytical methods for psychedelic research The company first applied for the exemption in October 2021, along with a Dealer’s License for commercializing psilocybin research and associated IP for medical and research purposes With this significant milestone, Delic Labs is leading the way in psychedelic compound testing and ensuring the safety and effectiveness of any treatments produced by them Delic’s management believes that the company is on the cusp of understanding the breadth of what is possible with psychedelics and medicine Back in October 2021, Delic…

TuesdayApr 19, 2022 1:38 pm

QualityStocksNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) to Participate at Sequire Cannabis and Psychedelic Conference, Scottsdale Capital Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that its co-founder and CEO Matt Stang will participate at the Sequire Cannabis and Psychedelic Conference and the Scottsdale Capital Event. Stang will present the company's performance and industry outlook and participate in one-on-one meetings with investors at the Sequire Cannabis and Psychedelic Conference. The virtual event, taking place on April 20, 2022, will bring together over 50 leading public companies in the cannabis, CBD and psychedelic space to discuss the future of their respective industries. In addition, Stang…

MondayApr 18, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Continues Expansion to Make Science-Backed Psychedelic Medicines Accessible to Patients with Mental Health Conditions

Delic opened two new KWC clinics in Q1 2022, bringing the total number of locations to 13, with plans to open more within the next 18 months The company also saw the introduction of SPRAVATO(R) nasal spray as a treatment option for treatment-resistant depression It is also expanding its ability to research novel compounds and develop IP for future commercialization Delic Holdings' (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Chief Executive Officer (“CEO”) and Co-founder, Matt Stang, has been keen to note the company’s commitment to bringing psychedelic medicine closer to individuals dealing with mental health conditions, particularly those with treatment-resistant…

WednesdayApr 13, 2022 12:11 pm

QualityStocksNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Health Canada 56 Exemption for Research on Psychedelic Compounds

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and its subsidiary Delic Labs have received a Health Canada 56 Research Exemption. The exemption gives approval for the company to conduct research and perform tests on several compounds, including MDMA, LSD, mescaline and 2C-B. The exemption also allows the lab to obtain psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc. The company anticipates moving forward and developing innovative analytical methods for psychedelic research. According to the announcement, the lab has also submitted an application for a dealer’s license with…

WednesdayApr 13, 2022 9:30 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Introduces FDA-Approved SPRAVATO(R) Nasal Spray at KWC Clinics in a Move to Make Mental health Treatment Effective and Affordable

Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings, just expanded its treatment options to include SPRAVATO(R) nasal spray beginning April 1 SPRAVATO received FDA approval back in 2019 and would be used in conjunction with an oral antidepressant Its introduction to KWC clinics underscores the company’s commitment to providing clinically-backed, accessible and affordable treatments to patients nationwide Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), through its wholly-owned subsidiary, Delic Labs, has remained committed to expanding its ability to research novel compounds and developing intellectual property (“IP”) for future commercialization of novel psychedelic compounds for medical use. So far,…

WednesdayApr 06, 2022 2:17 pm

QualityStocksNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Expanding Boundaries in Research of New Products

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is continually expanding its efforts to conduct and encourage even more research and education in support of high-quality products, such as psychedelics and cannabis, for the market. The company understands that research is integral for the rapidly developing psychedelics and cannabis industries, and for psychedelics to be widely adopted for treating mental issues. In addition, the company is helping reframe the psychedelic conversation while being at the forefront of the ongoing psychedelics renaissance. A recent article reads, “Delic’s focus on research is moving society closer to the full adoption…

MondayApr 04, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO to Present at Three Upcoming Investor Conferences Spotlighting the Company’s Strategic Outlook for the Remainder of 2022

Delic Holdings Co-founder and CEO, Matt Stang, will take part in three upcoming conferences – the Scottdale Capital Event, the Planet MicroCap Showcase, and the H.C. Wainwright Annual Global Life Sciences Conference In presentations and one-on-one meetings, Stang will discuss Delic’s new revenue lines and strategic outlook for the remainder of the year During a recent interview on The Jesse Tee Show, Stang noted the company intends to scale its ketamine clinics as well as build infrastructure to accommodate expanded psychedelic healing The company hopes to utilize its expanded infrastructure to help destigmatize mental health conditions Delic Holdings (CSE: DELC)…

ThursdayMar 31, 2022 11:09 am

QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces New Clinic Openings as Company’s Expansion Accelerates

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, is opening Ketamine Wellness Centers (“KWC”) in Salt Lake City and Reno, Nevada, with additional locations planned to open this year. The company also announced that it is adding SPRAVATO(R), the first FDA-approved nasal spray, as a treatment option at three of its ketamine centers; the spray is intended to treat adults with treatment-resistant depression and depressive symptoms of major depressive disorder. In addition, the the company’s Delic Labs received Health Canada 56 exemptions to perform research and development work for several substances, including MDMA,…

WednesdayMar 30, 2022 12:58 pm

QualityStocksNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Subsidiary Expands Treatment Options to Add FDA-Approved Esketamine Nasal Spray

Delic Holdings’ (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) subsidiary, Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S., has expanded its treatment options to include SPRAVATO(R) nasal spray. KWC clinics located in Houston, Las Vegas and Seattle will begin offering this treatment option on April 1. According to the announcement, SPRAVATO is taken with an oral antidepressant and is the first FDA-approved esketamine nasal spray for adults with treatment-resistant depression (“TRD”) or to treat depressive symptoms in adults with major depressive disorder (“MDD”) with suicidal thoughts or actions. Patients interested in the treatment option will first undergo…

Site Search

Company Search

Tag: Delic Corp Inc. DELCF